Clinical performance comparison of RAS mutation detection in plasma and tissue samples from stage IV colorectal cancer patients for first-line anti-EGFR therapy selection

被引：2

作者：

Hahn, S. ^{[1
]}

Tannapfel, A. ^{[2
]}

Friess, H. ^{[3
]}

Janssen, K. P. ^{[3
]}

Nitsche, U. ^{[3
]}

Slotta-Huspenina, J. ^{[4
]}

Pohl, M. ^{[5
]}

Vangala, D. B. ^{[5
]}

Jones, F. S. ^{[6
]}

Dockhorn-Dworniczak, B. ^{[7
]}

Hegewisch-Becker, S. ^{[8
]}

Schmiegel, W. ^{[5
]}

机构：

[1] Ruhr Univ Bochum, Dept Mol GI Oncol, Bochum, Germany

[2] Ruhr Univ Bochum, Univ Hosp Bergmannsheil, Dept Pathol, Bochum, Germany

[3] Tech Univ Munich, Klinikum Rechts Isar, Univ Hosp, Dept Surg, D-80290 Munich, Germany

[4] Tech Univ Munich, Dept Pathol, D-80290 Munich, Germany

[5] Ruhr Univ Bochum, Univ Hosp Knappschaftskrankenhaus, Dept Internal Med, Bochum, Germany

[6] Sysmex Inost Inc, Dept Med Affairs, Mundelein, IL USA

[7] Ctr Pathol, Kempten, Germany

[8] HOPE, Private Practice Hematol Oncol, Hamburg, Germany

来源：

关键词：

D O I：

10.1016/S0959-8049(16)30236-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

402

引用

页码：S79 / S79

页数：1